<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Alzheimer Res</journal-id><journal-id journal-id-type="iso-abbrev">Curr Alzheimer Res</journal-id><journal-id journal-id-type="publisher-id">CAR</journal-id><journal-title-group><journal-title>Current Alzheimer Research</journal-title></journal-title-group><issn pub-type="ppub">1567-2050</issn><issn pub-type="epub">1875-5828</issn><publisher><publisher-name>Bentham Science Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24156269</article-id><article-id pub-id-type="pmc">3979115</article-id><article-id pub-id-type="publisher-id">CAR-11-110</article-id><article-id pub-id-type="doi">10.2174/15672050113106660167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Prediction of Response to Galantamine Treatment in Patients with
Mild to Moderate Alzheimer&#x02019;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ohnishi</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Sakiyama</surname><given-names>Yojiro</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Okuri</surname><given-names>Yuichi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kimura</surname><given-names>Yuji</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sugiyama</surname><given-names>Nami</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Saito</surname><given-names>Takayuki</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Masayoshi</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kobayashi</surname><given-names>Takumi</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Scientific Affairs Division, CNS Science Department, Janssen Pharmaceutical K.K., Tokyo, Japan</aff><aff id="aff2"><label>2</label>Research and Development
Division, Department of Neuroscience, Janssen Pharmaceutical K.K., Tokyo, Japan</aff><aff id="aff3"><label>3</label>Research and Development
Division, Department of Clinical Science Initiatives, Janssen Pharmaceutical K.K., Tokyo, Japan</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at the Scientific Affairs Division,
CNS Science Department, Janssen Pharmaceutical K.K., 5-2, Nishi-kanda
3-chome, Chiyoda-ku, Tokyo 101-0065, Japan; Tel: +81-3-4411-5181;
Fax: +81-3-4411-5086; E-mail: <email xlink:href="tohnish8@its.jnj.com">tohnish8@its.jnj.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2014</year></pub-date><pub-date pub-type="epub"><month>2</month><year>2014</year></pub-date><volume>11</volume><issue>2</issue><fpage>110</fpage><lpage>118</lpage><history><date date-type="received"><day>19</day><month>11</month><year>2012</year></date><date date-type="rev-recd"><day>25</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>9</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Bentham Science Publishers</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical
issue, although no consistently strong predictive factors have emerged thus far. The present analyses aimed to identify factors
for predicting long-term outcome of galantamine treatment. Analyses were conducted with data from a 24 weeks randomized,
double-blind, placebo controlled trial to evaluate the efficacy and the safety of galantamine in the treatment of
303 patients with mild to moderate AD. Patients were divided into responders (4 or more point improvement of ADAS-cog
scores at 24 weeks of treatment) and non-responders. We explored whether patients&#x02019; background (e.g. sex, age, and
duration of disease) and scores of cognitive scales at early stage, are relevant to the long-term response to AChEIs. Predictive
values were estimated by the logistic regression model. The responder rate was 31.7 %. We found that changes in
scores of ADAS-J cog subscales between week 4 and baseline, especially word recognition, can be a good variable to predict
subsequent response to galantamine, with approximately 75% of predictive performance. Characteristics of patients,
including demographic characteristics, severity of disease and neuropsychological features before treatment were poorly
predictive. The present study indicate that initial response to galantamine administration in patients with mild to moderate
AD seems to be a reliable predictor of response of consequent galantamine treatment. Patients who show improvement of
episodic memory function during the first 4 weeks of galantamine administration may be likely to particularly benefit
from galantamine treatment.</p></abstract><kwd-group><title>Keywords:</title><kwd>Acetylcholinesterase inhibitor</kwd><kwd>Alzheimer's disease</kwd><kwd>Alzheimer&#x02019;s disease assessment scale-cognitive subscale
(ADAS-cog)</kwd><kwd>galantamine, pharmacotherapy</kwd><kwd>responders.</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Alzheimer&#x02019;s disease (AD) is the most common form of dementia, affecting over 25 million people in the world [<xref rid="R1" ref-type="bibr">1</xref>]. At present, there are no therapeutic interventions that halt or reverse disease progression, and the currently available medications, typically acetyl cholinesterase inhibitors (AChEIs), are just a palliative therapy for AD symptoms. Various AChEIs have been used in Europe, the United States and Asia, most of which have shown significant clinical efficacy and safety in the treatment of AD. Galantamine hydrobromide (Reminyl<sup>&#x000ae;</sup>) is one of such AChEIs for patients with mild to moderate AD. Galantamine is characterized by two pharmacological mechanisms, inhibition of acetylcholine esterase and allosterically modulating ligand actions by binding to nicotinic acetylcholine receptors [<xref rid="R2" ref-type="bibr">2</xref>]. Galantamine maintains acetylcholine concentration in the synaptic cleft by the two mechanisms and thereby compensate the decline of cholinergic function in AD patients.</p><p>Although options for pharmacotherapy of AD have been extending, there still has been no consistent position and little supporting evidence on how to choose optimal treatment for patients. In addition, the efficacy of AChEIs is known to differ between patients. Although main efficacy of AChEIs is represented as slowing the cognitive decline caused by AD pathology, some patients treated with AChEIs, so called &#x02018;responder&#x02019; show significant improvement of cognitive symptoms. Several studies demonstrated that about one third of patients treated with AChEIs showed such a significant response [<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr"> 4</xref>]. Patients with dementia, caregivers, and physicians are concerned with clinically important improvement rather than statistical significances demonstrating clinical trials. Several studies have used a change of 4 points or more on the ADAS-cog scale to define a clinically important improvement for mild to moderate dementia [<xref rid="R5" ref-type="bibr">5</xref>]. In this context, the prediction who would be likely to be a responder is a clinically important issue.</p><p>The prediction of response to AChEIs has been investigated in various aspects (see Table <bold><xref ref-type="table" rid="T3">3</xref></bold>); 1) prediction based on neuropsychiatric features [<xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R8" ref-type="bibr">8</xref>], 2) prediction based on genetic features, mostly ApoE4 genotype [<xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R15" ref-type="bibr">15</xref>], 3) prediction based on the neurochemical features, including CSF biomarkers such as amyloid beta and tau [<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R16" ref-type="bibr"> 16</xref>], 4) prediction based on neurological features [<xref rid="R17" ref-type="bibr">17</xref>-<xref rid="R25" ref-type="bibr">25</xref>] and 5) prediction using multivariate including sex, age, ApoE genotype, etc [<xref rid="R26" ref-type="bibr">26</xref>]. However, high-accuracy predictors have not been identified thus far, which closely linked to response to AChEIs.</p><p>We therefore investigated predictive factors associated with response of galantamine treatment on cognitive symptoms, by a post-hoc analysis of a 24 weeks randomized, double-blind, placebo controlled trial to evaluate the efficacy and the safety of galantamine in the treatment of Japanese patients with mild to moderate AD (A clinical trials in Japan: GAL-JPN-5; ClinicalTrials.gov Identifier:NCT00814801) [<xref rid="R27" ref-type="bibr">27</xref>].</p></sec><sec><title>SUBJECTS/MATERIALS AND METHODS</title><sec><title>Subjects</title><p>Subjects were mild to moderate AD patients participated in the GAL-JPN-5 (ClinicalTrials.gov Identifier: NCT00814801) [<xref rid="R27" ref-type="bibr">27</xref>]. GAL-JPN-5 is a Japan Phase &#x02162; study conducted from January 2006 to September 2008 to assess the effect of galantamine on patients with mild to moderate AD. The study was a multicenter, randomized, double-blind, placebo-controlled trial. Patients initially underwent 4 weeks of observation period, followed by 24 weeks of double-blinded study period. Patients were not eligible to enter the double-blinded study if they received other anti-AD drugs (donepezil, rivastigmine, memantine) during the observation period. Patients were eligible to enter the trial if they met all of the following criteria; 1) A diagnosis of probable AD according to criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer&#x02019;s Disease and Related Disorders Association (NINCDS-ADRDA) [<xref rid="R28" ref-type="bibr">28</xref>] with Mini-Mental State Examination (MMSE) [<xref rid="R29" ref-type="bibr">29</xref>] scores between 10 and 22, and with ADAS-J cog total scores not less than 18, scores of both orientation and word recall not less than 1, and with Mental Function Impairment Scale (MENFIS) [<xref rid="R30" ref-type="bibr">30</xref>] scores of both space and time orientation not less than 1. 2) No coexisting other neurodegenerative disease. Patients were initially randomized in a 1:1:1 ratio to placebo, galantamine 16 mg or 24 mg. During dose escalation, patients in the galantamine group received 4 mg twice daily for weeks 1-4 and 8 mg twice daily for weeks 5-8. During the weeks 9-24, patients in the 16 mg/day group received 8 mg twice daily, and patients in the 24 mg/day group received 12 mg twice daily.</p></sec><sec><title>Datasets</title><p>Datasets of the Japanese version of the Alzheimer&#x02019;s Disease Assessment Scale-cognitive subscale (ADAS-J cog) [<xref rid="R31" ref-type="bibr">31</xref>] up to 24 weeks were used for the present analyses and excluded data that were not completed until 24 weeks. The analysis datasets included a group underwent galantamine treatment with a maintenance dose of 16 mg/day (N=153) and a group with that of 24 mg/day (N=150) (totally N=303). </p></sec><sec><title>Classification of Responders/Non-responders</title><p>Among the galantamine-treated groups, patients whose ADAS-J cog scores improved by 4 or more points at 24 weeks of treatment were classified as responders and others were classified as non-responders, according to the definition of &#x0201c;responder&#x0201d; described in NICE guideline [<xref rid="R32" ref-type="bibr">32</xref>].</p></sec><sec><title>Screening of Predictive Factors</title><p>Based on the definition above, among the total 303 subjects 96 (31.7%) were classified as responders and 207 (68.3%) were classified as non-responders. Data were subsequently divided equally into two parts (2-fold cross validation), one is for modeling (responder: 48, non-responder: 104) and the other is for prediction (responder: 48, non-responder: 103). By random sampling with replacement (bootstrapping), 10 pairs of each dataset were produced. The factors examined are daily dosage of galantamine, demographic factors, scores of MMSE at baseline, scores of ADAS-J cog at baseline, scores of ADAS-J cog at week 4, the difference between at week 4 and baseline of the ADAS-J cog, scores of MMSE subscales at baseline, scores of ADAS-J cog subscales at baseline, scores of ADAS-J cog subscales at week 4 and the difference between them. We analyzed data at week 4 since it could be beneficial for physicians to provide patients with optimal treatment regimen at early stage of AD. Details are described as follows;
<list list-type="order"><list-item><p>Daily dosage of galantamine (16mg, 24mg)</p></list-item><list-item><p>Demographic factors: sex, age, disease duration</p></list-item><list-item><p>Scores of MMSE at baseline, scores of ADAS-J cog at baseline, scores of ADAS-J cog at week 4, and the difference between them.</p></list-item><list-item><p>Scores of MMSE subscales at baseline: orientation (year, season, day, month, date, prefecture, city, hospital, floor, district), recall (objects, number), calculation, delayed recall, language (pencil, watch), reading, command (take a paper, fold it in half, put it on the desk), command (write a sentence), writing and drawing</p></list-item><list-item><p>Scores of ADAS-J cog subscales at baseline: word recall, language, comprehension of spoken language, word finding difficulty, commands, naming objects and fingers, constructional praxis, ideational praxis, orientation, word recognition task, word recall task (abbreviated as follows; recall, language, comprehension, finding, commands, naming, constructional, ideational, orientation, word recognition, task)</p></list-item><list-item><p>Scores of ADAS-J cog subscales at week 4: same as above</p></list-item><list-item><p>Difference between week 4 and baseline of the scores of ADAS-J cog subscales: same as above</p></list-item></list>
</p><p>First of all we calculated effect size of these scores, i.e., we compared difference of the scores of the factors between the responder and the non-responder groups divided by their pooled standard deviation with the use of dataset for modeling, with an underlying assumption that the factor having larger effect size could have higher predictive performance.</p></sec><sec><title>Validation of Predictive Performance</title><p>After the screening of the predictive factors described above, a factor with the largest effect size was treated as the most predictive factor. Then a logistic regression analysis was conducted with the responder/non-responder as the binary response variables, and the scores of subscales of the factor as explanatory variables. Firstly, all variables were used for model building as a full model. Secondly, selected variables (significant by Wald&#x02019;s chi-square, p&#x0003c;0.05) were used for model building as partial models. By maximum likelihood method the regression parameters (coefficients) of the logistic model were determined using the dataset for modeling. Then the model was applied to the other dataset for prediction. These datasets were produced by 1000 times of resampling (bootstrapping). Predictive performance was assessed by receiver operating characteristics (ROC) curve [<xref rid="R33" ref-type="bibr">33</xref>]. The endpoints of the predictive performance are the area under the curve (AUC) of ROC, sensitivity and specificity. The sensitivity* and specificity* were determined at the cutoff point where sensitivity-(1-specificity) is maximal in the ROC curve.</p></sec><sec><title>Statistical Analysis</title><p>All statistical analyses were conducted with the use of SAS<sup>&#x000ae;</sup>9.2 (SAS Institute Inc., Cary, NC, USA)</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Responder Rate</title><p>Among 303 patients received galantamine, 96 (31.7%) were classified as responders. Among the 96 responders, 44 underwent maintenance dose of 16 mg/day, and 52 underwent that of 24 mg/day. Among the 207 non-responders, 109 underwent maintenance dose of 16 mg/day, and 98 underwent that of 24 mg/day. The association between the two categorical variables (responder/non-responder, 16mg/24mg) was not significant (p=0.326, by chi-square test of independence).</p></sec><sec><title>Effect Size of the Factors Examined</title><p>The effect size of each factor was summarized as shown in (Fig. <bold><xref ref-type="fig" rid="F1">1</xref></bold>).</p><p>Among the mean values described above, the effect size of the difference between at week 4 and at baseline of the scores of ADAS-J cog subscales was the largest of all factors (nearly 0.3). Among the differences of the ADAS-J cog subscales, the effect size of the score of word recognition was the largest, which was nearly 0.8. It can be concluded that change in the scores of ADAS-J cog subscales at week 4 from baseline was the most predictive factor, thus the subscales were used as input variables for the following logistic regression analysis.</p></sec><sec><title>Predictive Performance</title><p>The predictive performance was estimated by ROC curves as shown in (Fig. <bold><xref ref-type="fig" rid="F2">2</xref></bold>), using scores of all 11 subscales of the difference between week 4 and baseline of ADAS-J cog as input variables (full model).</p><p>The results of AUC of ROC, sensitivity and specificity using the full model were as follows (mean &#x000b1; standard deviation). </p><table-wrap id="T" position="anchor"><table frame="void" rules="none" width="100%"><tbody><tr><td rowspan="1" colspan="1">AUC of ROC:</td><td rowspan="1" colspan="1">0.808&#x000b1;0.029</td><td rowspan="1" colspan="1">(modeled),</td><td rowspan="1" colspan="1">0.732&#x000b1;0.033</td></tr><tr><td rowspan="1" colspan="1">(predicted)</td></tr><tr><td rowspan="1" colspan="1">Sensitivity:</td><td rowspan="1" colspan="1">0.750&#x000b1;0.074</td><td rowspan="1" colspan="1">(modeled),</td><td rowspan="1" colspan="1">0.690&#x000b1;0.087</td></tr><tr><td rowspan="1" colspan="1">(predicted)</td></tr><tr><td rowspan="1" colspan="1">Specificity:</td><td rowspan="1" colspan="1">0.789&#x000b1;0.070</td><td rowspan="1" colspan="1">(modeled),</td><td rowspan="1" colspan="1">0.735&#x000b1;0.084</td></tr><tr><td rowspan="1" colspan="1">(predicted)</td></tr></tbody></table></table-wrap><p>The regression parameters, Wald&#x02019;s chi-square, p-values, adjusted odds ratios and their 95% confidence intervals are summarized in (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). As shown in (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>), the significant variables were ideational, orientation and word recognition. Then we scrutinized these variables into one or two variables to elucidate their predictive performance. As also shown in (Table <bold><xref ref-type="table" rid="T2">2</xref></bold>), the most predictive variable was recognition. The predictive performance, ROC_AUC, sensitivity and specificity of the full model (11 items of ADAS J-cog) and the partial models (Ideational + Orientation + Word recognition, Ideational + Word recognition, Ideational alone, Orientation alone and Word recognition alone) with the use of datasets for prediction were as follows</p><p>AUC of ROC: 0.732&#x000b1;0.033 (full model), 0.729&#x000b1;0.033 (Ideational + Orientation + Word recognition,), 0.721&#x000b1;0.032 (Ideational + Word recognition), 0.602&#x000b1;0.035 (Ideational alone), 0.547&#x000b1;0.053 (Orientation alone), 0.710&#x000b1;0.032 (Word recognition alone)</p><p>Sensitivity: 0.690&#x000b1;0.087 (full model), 0.650&#x000b1;0.096 (Ideational + Orientation + Word recognition,), 0.709&#x000b1;0.089 (Ideational + Word recognition), 0.521&#x000b1;0.131 (Ideational alone), 0.478&#x000b1;0.275 (Orientation alone), 0.749&#x000b1;0.059 (Word recognition alone) </p><p>Specificity: 0.735&#x000b1;0.084 (full model), 0.749&#x000b1;0.088 (Ideational + Orientation + Word recognition,), 0.683&#x000b1;0.085 (Ideational + Word recognition), 0.640&#x000b1;0.047 (Ideational alone), 0.632&#x000b1;0.277 (Orientation alone), 0.640&#x000b1;0.047 (Word recognition alone).</p><p>The order of predictive performance was word recognition &#x0003e; ideational &#x0003e; orientation. The predictive performance by the full model (11 variables), 3 variables, 2 variables and word recognition were almost equivalent (moderate accuracy).</p><p>Since among the ADAS-J cog subscales, word recognition was found to be the most predictive subscale when assessed difference of their scores between week 4 and baseline. The score and its relevance to the incidence of response were depicted in the (Fig. <bold><xref ref-type="fig" rid="F3">3</xref></bold>), which showed that incidence of response was larger when the score was lower. The mean value of the score was -1.49, indicating that long-term response to galantamine could be predicted when change of the score of word recognition at week 4 from baseline is around 1.5.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In the present study, we retrospectively analyzed data from a randomized, double-blind, placebo controlled trial to evaluate the efficacy and the safety of galantamine in the treatment of 303 patients with mild to moderate AD. We found that response to galantamine treatment, i.e., whether &#x02018;responder&#x02019; or &#x02018;non-responder&#x02019;, can be predictable by the changes of the scores of subscales of the ADAS-J cog, especially, improvement of word recognition during the first 4 weeks of galantamine administration. The result suggests that changes in episodic memory function caused by initial galantamine treatment, even at the titration period, should be a predictor of the response to consequent galantamine treatment. Patients who show improvement of episodic memory function during the first 4 weeks of galantamine administration may be likely to be particularly beneficial to subsequent galantamine treatment. Similar results were reported by Kavanagh <italic>et al.</italic>, where they analyzed six randomized, double-blind, and placebo controlled trials of galantamine treatment and found the relationship between short term (2-5 month) response to galantamine treatment and long term (18 months) benefit of galantamine treatment [<xref rid="R34" ref-type="bibr">34</xref>]. Although the evaluated period for both predictor and long-term outcome were different, the result of their study is essentially the same as that of ours, in terms of the fact that initial response to galantamine treatment could be a reliable predictor for long-term outcome of galantamine treatment. A study with Baysian statistics also demonstrated the highly significant correlation between the short-term response and the long-term one [<xref rid="R35" ref-type="bibr">35</xref>].</p><p>It is noteworthy that dosage, demographic characteristics, and scores of cognitive subscales at baseline were poorly predictive. It suggests that prediction of long-term response to galantamine treatment by using pre-treatment information should be difficult.</p><p>Several studies have attempted to find predictors of AChEIs treatment as summarized in (Table <bold><xref ref-type="table" rid="T3">3</xref></bold>). However, no consistently strong factors have emerged thus far [<xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R26" ref-type="bibr">26</xref>]. For example, ApoE polymorphism is a well known risk factor of getting AD and its disease progression [<xref rid="R36" ref-type="bibr">36</xref>]. Furthermore, ApoE4 genotype is associated with lower ChAT levels and a more severe cholinergic deficit, therefore, the presence of the risk allele may predict a poorer response to AChEI therapy [<xref rid="R37" ref-type="bibr">37</xref>]. However, the results of studies that assessed whether ApoE genotype was a predictor of response to AChEI therapy were inconsistent [<xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R15" ref-type="bibr">15</xref>]. One possibility for such varying results is that the studies involve different AChEIs. Although all of them inhibit AChE, other pharmacologic aspects of the compounds differ. Theoretically, such differences may translate to clinical differences, but the similarity of response rates among different AChEIs suggests that the mechanism of the effect should be similar. Indeed, the responder rate of the present study was 31.7 % and was similar to those of previous studies [<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr"> 4</xref>]. Another possibility is the methodological differences, including difference in the study design (open-label or blinded), difference in the period of treatment and evaluation, difference in applied cognitive scales (ADAS-cog or MMSE), and the consequent differences of definition of the &#x02018;responder&#x02019; amongst the studies could contribute to the discrepancies among the studies.</p><p>The present study has two advantages over previous studies. First, the present results were obtained from a double blind, randomized, placebo-controlled trial with a large sample size. Several previous studies of prediction of response to AChEI treatment were done with the data from open label trials with relatively small samples [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R12" ref-type="bibr"> 12</xref>,<xref rid="R17" ref-type="bibr"> 17</xref>,<xref rid="R18" ref-type="bibr"> 18</xref>,<xref rid="R24" ref-type="bibr"> 24</xref>]. Second, most of the previous studies did not perform cross-validation of the predictive models, thus the results could be model-specific and labile [<xref rid="R38" ref-type="bibr">38</xref>]. Therefore, replication of the results across the studies should be necessary to generalize the results of the studies. On the other hand, we applied a two-fold cross-validation, in which we split the data into two subsets, one for model building and the other for validation. The subsets were randomly sampled with replacement 1000 times (bootstrapping). Such a procedure allows us to generalize the results of the present study. Therefore, we believe that initial improvement of episodic memory function after galantamine administration could be a reliable predictor of preferable long-term outcomes and our predictive model could be applied to other cohorts.</p><p>Amongst the possible predictors of improvement in cognitive outcomes, qualitative electroencephalogram profile after a single dose of tacrine was consistently found to be a good predictor of cognitive response. However, 3 out of 4 studies were open label and all the study were conducted with small samples [<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr"> 18</xref>,<xref rid="R24" ref-type="bibr"> 24</xref>]. Prospective trials with second-generation AChEIs should be preferable. Disease progression rate seems to be another reliable predictor. Farlow <italic>et al.</italic> studied the data from a multicentre, double-blind, randomized, placebo-controlled trial of rivastigmine (and open-label extension) to assess the relation between AD progression rate and response to rivastigmine [<xref rid="R6" ref-type="bibr">6</xref>]. They found that patients with rapidly progressing symptoms measured by ADAS-cog and Progressive Deterioration Scale were more likely to respond to rivastigmine treatment [<xref rid="R6" ref-type="bibr">6</xref>]. Considering the clinical setting in the real world, however, it is difficult to evaluate accurately disease progression rate before start of the treatment. Contrary to disease progression rate, initial improvement of recent memory function measured by the delayed recall test is easy to assess in the clinical setting. </p><p>What are underlying mechanisms of the results of our study? We assume that both initial and long-term response to galantamine administration might be associated with functional state of the cerebral cholinergic system in each patient. Although the functional status of the cholinergic system is thought to contribute significantly to symptoms in AD, the degree of brain pathology in AD does not often have a direct relationship to the degree of clinical symptoms [<xref rid="R39" ref-type="bibr">39</xref>]. Recent studies revealed that so called &#x02018;cognitive reserve&#x02019; should be associated with such a discrepancy [<xref rid="R40" ref-type="bibr">40</xref>]. We consider that severity of disease and neuropsychological features before treatment may be affected by &#x02018;cognitive reserve&#x02019; as well as pathology of AD and do not precisely reflect functional state of the cerebral cholinergic system in each AD patient, therefore, severity of disease and/or neuropsychological features is not a good predictor for long-term outcomes of AChEIs treatment. Considering the intimate relationship between episodic memory function and the cerebral cholinergic system, initial changes of recent memory function caused by pharmacological intervention might be one of reliable markers of functional status of the cerebral cholinergic system in each AD patient. A recent pharmacological functional magnetic resonance imaging (ph fMRI) study demonstrated that galantamine challenge affected brain activity during the face recognition task in memory related brain regions in AD and mild cognitive impairment, suggesting that ph fMRI challenge tests should prove to be a valuable instrument to examine the functional status of central neurotransmitter systems in a disease and be helpful to assess neurotransmitter system pathology, to monitor disease progression and to predict response to pharmacological therapy [<xref rid="R41" ref-type="bibr">41</xref>]. Since the accuracy of our predictive model was moderate, future studies combining molecular imaging techniques (e.g. Positron Emission Tomography) and ph fMRI in order to relate cholinergic receptor status to signal changes in specific brain structures and corresponding clinical phenotypes (initial response to galantamine treatment) would clarify our speculation and would improve the accuracy of our predictive model.</p><p>Finally, several limitation of the present study should be mentioned. Firstly, this is a retrospective analysis of the data from a study with a relatively short term period (24week), therefore prospective studies with a longer treatment period are required to validate our results. However, the timing of decision making for switching one type of ChEIs to another type of ChEI is 6 months after the start of treatment [<xref rid="R42" ref-type="bibr">42</xref>]. The present study suggests the possibility of early decision making of strategy of pharmacological treatment of AD. Secondary, some important patient characteristics associated with disease progression and risk of disease, such as ApoE genotype and education level were not collected. However, as mentioned previously, results of studies to investigate relationship between ApoE genotype and response to AChEIs treatment were inconsistent [<xref rid="R9" ref-type="bibr">9</xref>-<xref rid="R15" ref-type="bibr">15</xref>]. Furthermore, four randomized placebo-controlled trials with large samples agreed that ApoE was not a good predictor of response to AChEIs [<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R11" ref-type="bibr"> 11</xref>,<xref rid="R14" ref-type="bibr"> 14</xref>,<xref rid="R15" ref-type="bibr"> 15</xref>]. We are skeptical about the possibility that further study of ApoE could reveal an important difference. Lower education level is also known to be a well known risk factor of Alzheimer&#x02019;s disease [<xref rid="R43" ref-type="bibr">43</xref>]. <italic>Wattmo et al.</italic> reported an opposite effect of education level on long-term outcome of AD, high education level was a risk factor of faster cognitive decline [<xref rid="R26" ref-type="bibr">26</xref>]. Future studies are warranted to clarify how education level affects long-term response to AChEIs treatment.</p><p>In conclusion, initial response to galantamine administration in patients with mild to moderate AD seems to be a reliable predictor of subsequent galantamine treatment. Although several issues remain to be clarified, the results of the present study suggest that galantamine have greater treatment effects in patients who show improvement of recent memory function during the first 4 weeks of galantamine administration.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>The authors would like to thank Dr. Akira Homma, Tokyo Dementia Care Research and Training Center, and Dr. Yu Nakamura, Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, for their valuable advices. All authors are employees of Janssen Pharmaceutical K.K.</p></ack><sec><title>CONFLICT OF INTEREST</title><p>The authors confirm that this article content has no conflicts of interest.</p></sec><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brookmeyer</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Ziegler-Graham</surname><given-names>K</given-names></name><name><surname>Arrighi</surname><given-names>HM</given-names></name></person-group><article-title>Forecasting the global burden of alzheimer's disease</article-title><source>Alzheimers Dement</source><year>2007</year><volume>3</volume><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">19595937</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagino</surname><given-names>K</given-names></name><name><surname>Shikinami</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Harada</surname><given-names>Y</given-names></name></person-group><article-title>Pharmacological and
clinical profiles of galantamine (reminyl((r)))]</article-title><source>Nihon Yakurigaku Zasshi</source><year>2011</year><volume>138</volume><fpage>122</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">21908940</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacobini</surname><given-names>E</given-names></name></person-group><article-title>Cholinesterase inhibitor therapy stabilizes symptoms of alzheimer disease</article-title><source>Alzheimer Dis Assoc Disord</source><year>2000</year><volume>14 1</volume><issue>1</issue><fpage>S3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">10850724</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>HP</given-names></name><name><surname>Korbey</surname><given-names>J</given-names></name><name><surname>Wilkinson</surname><given-names>DG</given-names></name><name><surname>Rowden</surname><given-names>J</given-names></name></person-group><article-title>Donepezil in alzheimer's disease: Eighteen month results from southampton memory clinic</article-title><source>Int J Geriatr Psychiatry</source><year>2000</year><volume>15</volume><fpage>713</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">10960883</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raina</surname><given-names>P</given-names></name><name><surname>Santaguida</surname><given-names>P</given-names></name><name><surname>Ismaila</surname><given-names>A</given-names></name><name><surname>Patterson</surname><given-names>C</given-names></name><name><surname>Cowan</surname><given-names>D</given-names></name><name><surname>Levine</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><issue>5</issue><fpage>379</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">18316756</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Hake</surname><given-names>A</given-names></name><name><surname>Messina</surname><given-names>J</given-names></name><name><surname>Hartman</surname><given-names>R</given-names></name><name><surname>Veach</surname><given-names>J</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name></person-group><article-title>Response of patients with alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression</article-title><source>Arch Neurol</source><year>2001</year><volume>58</volume><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">11255445</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mega</surname><given-names>MS</given-names></name><name><surname>Masterman</surname><given-names>DM</given-names></name><name><surname>O'Connor</surname><given-names>SM</given-names></name><name><surname>Barclay</surname><given-names>TR</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name></person-group><article-title>The spectrum of behavioral responses to cholinesterase inhibitor therapy in alzheimer disease</article-title><source>Arch Neurol</source><year>1999</year><volume>56</volume><fpage>1388</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">10555660</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallin</surname><given-names>AK</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name></person-group><article-title>Can csf biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in alzheimer's disease?</article-title><source>Int J Geriatr Psychiatry</source><year>2009</year><volume>24</volume><fpage>638</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">19123199</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aerssens</surname><given-names>J</given-names></name><name><surname>Raeymaekers</surname><given-names>P</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name><name><surname>Geerts</surname><given-names>H</given-names></name><name><surname>Konings</surname><given-names>F</given-names></name><name><surname>Parys</surname><given-names>W</given-names></name></person-group><article-title>Apoe genotype: No influence on galantamine treatment efficacy nor on rate of decline in alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2001</year><volume>12</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">11173877</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>R</given-names></name><name><surname>Kudaravalli</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><article-title>Differential qualitative responses to rivastigmine in apoe epsilon 4 carriers and noncarriers</article-title><source>Pharmacogenomics J</source><year>2004</year><volume>4</volume><fpage>332</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">15289797</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Cyrus</surname><given-names>PA</given-names></name><name><surname>Nadel</surname><given-names>A</given-names></name><name><surname>Lahiri</surname><given-names>DK</given-names></name><name><surname>Brashear</surname><given-names>A</given-names></name><name><surname>Gulanski</surname><given-names>B</given-names></name></person-group><article-title>Metrifonate treatment of ad: Influence of apoe genotype</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>2010</fpage><lpage>2016</lpage><pub-id pub-id-type="pmid">10599773</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oddoze</surname><given-names>C</given-names></name><name><surname>Michel</surname><given-names>B</given-names></name><name><surname>Lucotte</surname><given-names>G</given-names></name></person-group><article-title>Apolipoprotein e e4 allele predicts a better response to donepezil therapy in alzheimer's disease</article-title><source>Alzheimer's Report</source><year>2000</year><volume>3</volume><fpage>213</fpage><lpage>216</lpage></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>GH</given-names></name><name><surname>Jung</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>CU</given-names></name><name><surname>Oh</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effect of the apolipoprotein e epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2006</year><volume>21</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">16254428</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name><name><surname>Gaens</surname><given-names>E</given-names></name></person-group><article-title>Efficacy and safety of galantamine
in patients with mild to moderate alzheimer's disease: Multicentre
randomised controlled trial. Galantamine international-1
study group</article-title><source>BMJ</source><year>2000</year><volume>321</volume><fpage>1445</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">11110737</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Engedal</surname><given-names>K</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Verhey</surname><given-names>F</given-names></name><name><surname>Waldemar</surname><given-names>G</given-names></name><name><surname>Wimo</surname><given-names>A</given-names></name><etal/></person-group><article-title>A 1-year, randomized, placebo-controlled study of donepezil
in patients with mild to moderate ad</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">11502918</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobow</surname><given-names>T</given-names></name><name><surname>Kloszewska</surname><given-names>I</given-names></name><name><surname>Flirski</surname><given-names>M</given-names></name><name><surname>Liberski</surname><given-names>P</given-names></name></person-group><article-title>Predictors of long-term
treatment effect of rivastigmine in alzheimer's disease: A role
for beta-amyloid plasma levels?</article-title><source>Neurol Neurochir Pol</source><year>2009</year><volume>43</volume><fpage>507</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">20054753</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhainen</surname><given-names>K</given-names></name><name><surname>Partanen</surname><given-names>J</given-names></name><name><surname>Reinikainen</surname><given-names>K</given-names></name><name><surname>Laulumaa</surname><given-names>V</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Airaksinen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-eeg in patients with alzheimer's disease</article-title><source>Neurosci Lett</source><year>1991</year><volume>127</volume><fpage>113</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">1881606</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhainen</surname><given-names>K</given-names></name><name><surname>Riekkinen</surname><given-names>PJ</given-names><suffix>Sr</suffix></name></person-group><article-title>Discrimination of alzheimer patients responding to cholinesterase inhibitor therapy</article-title><source>Acta Neurol Scand Suppl</source><year>1993</year><volume>149</volume><fpage>16</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">7907454</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almkvist</surname><given-names>O</given-names></name><name><surname>Jelic</surname><given-names>V</given-names></name><name><surname>Amberla</surname><given-names>K</given-names></name><name><surname>Hellstrom-Lindahl</surname><given-names>E</given-names></name><name><surname>Meurling</surname><given-names>L</given-names></name><name><surname>Nordberg</surname><given-names>A</given-names></name></person-group><article-title>Responder characteristics to a single oral dose of cholinesterase inhibitor: A double-blind placebo-controlled study with tacrine in alzheimer patients</article-title><source>Dement Geriatr Cogn Disord</source><year>2001</year><volume>12</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">11125238</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babiloni</surname><given-names>C</given-names></name><name><surname>Cassetta</surname><given-names>E</given-names></name><name><surname>Dal Forno</surname><given-names>G</given-names></name><name><surname>Del Percio</surname><given-names>C</given-names></name><name><surname>Ferreri</surname><given-names>F</given-names></name><name><surname>Ferri</surname><given-names>R</given-names></name><etal/></person-group><article-title>Donepezil effects on sources of cortical rhythms in mild
alzheimer's disease: Responders vs. Non-responders</article-title><source>Neuroimage</source><year>2006</year><volume>31</volume><fpage>1650</fpage><lpage>1665</lpage><pub-id pub-id-type="pmid">16600641</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Chisholm</surname><given-names>JA</given-names></name><name><surname>Owens</surname><given-names>J</given-names></name><name><surname>Pimlott</surname><given-names>S</given-names></name><name><surname>Patterson</surname><given-names>J</given-names></name><name><surname>Wyper</surname><given-names>D</given-names></name></person-group><article-title>Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with alzheimer's disease</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2003</year><volume>30</volume><fpage>296</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">12552349</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connelly</surname><given-names>PJ</given-names></name><name><surname>Prentice</surname><given-names>NP</given-names></name><name><surname>Fowler</surname><given-names>KG</given-names></name></person-group><article-title>Predicting the outcome of cholinesterase inhibitor treatment in alzheimer's disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2005</year><volume>76</volume><fpage>320</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">15716519</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanetaka</surname><given-names>H</given-names></name><name><surname>Hanyu</surname><given-names>H</given-names></name><name><surname>Hirao</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Akai</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prediction of response to donepezil in alzheimer's disease: Combined mri analysis of the substantia innominata and spect measurement of cerebral perfusion</article-title><source>Nucl Med Commun</source><year>2008</year><volume>29</volume><fpage>568</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">18458605</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knott</surname><given-names>V</given-names></name><name><surname>Mohr</surname><given-names>E</given-names></name><name><surname>Mahoney</surname><given-names>C</given-names></name><name><surname>Ilivitsky</surname><given-names>V</given-names></name></person-group><article-title>Pharmaco-eeg test dose response predicts cholinesterase inhibitor treatment outcome in alzheimer's disease</article-title><source>Methods Find Exp Clin Pharmacol</source><year>2000</year><volume>22</volume><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">10849895</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>A</given-names></name><name><surname>Hashimoto</surname><given-names>H</given-names></name><name><surname>Kawabe</surname><given-names>J</given-names></name><name><surname>Higashiyama</surname><given-names>S</given-names></name><name><surname>Kai</surname><given-names>T</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evaluation of therapeutic response to donepezil by positron emission tomography</article-title><source>Osaka City Med J</source><year>2011</year><volume>57</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">22106763</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wattmo</surname><given-names>C</given-names></name><name><surname>Wallin</surname><given-names>AK</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name></person-group><article-title>Predictors of long-term cognitive outcome in alzheimer's disease</article-title><source>Alzheimers Res Ther</source><year>2011</year><volume>3</volume><fpage>23</fpage><pub-id pub-id-type="pmid">21774798</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homma</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Shikinami</surname><given-names>K</given-names></name><name><surname>Ishida</surname><given-names>R</given-names></name></person-group><article-title>A placebo-controlled, double-blind, comparative study of galantamine
hydrobromide in patients with alzheimer-type dementia</article-title><source>Jpn J
Geriatr Psychiatry</source><year>2011</year><volume>22</volume><fpage>333</fpage><lpage>345</lpage></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homma</surname><given-names>A</given-names></name><name><surname>Fukuzawa</surname><given-names>K</given-names></name><name><surname>Tsukada</surname><given-names>Y</given-names></name></person-group><article-title>Development of a japanese version of alzheimer's disease assessment scale (adas)</article-title><source>Jpn J Geriatr Psychiatry</source><year>1992</year><volume>3</volume><fpage>647</fpage><lpage>655</lpage></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="webpage"><source>NICE. Donepezil, galantamine, rivastigmine (review) memantine
for the treatment of alzheimer's disease (amended) includes a review
of nice technology appraisal guidance 19 <uri xlink:type="simple" xlink:href="http://www.Nice.Org.Uk/nicemedia/pdf/ta111guidanceamendedaug09.Pdf">http://www.Nice.Org.Uk/nicemedia/pdf/ta111guidanceamendedaug09.Pdf</uri>. NICE technology appraisal guidance 111 (amended)</source><year>2009</year></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Obunchowski</surname><given-names>N</given-names></name><name><surname>McClish</surname><given-names>D</given-names></name></person-group><source>Statistical methods in diagnostic
medicine</source><year>2002</year><edition>1st ed</edition><publisher-loc>New York</publisher-loc><publisher-name>John Wiley &#x00026; Sons</publisher-name><fpage>15</fpage><lpage>164</lpage></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavanagh</surname><given-names>S</given-names></name><name><surname>Howe</surname><given-names>I</given-names></name><name><surname>Brashear</surname><given-names>HR</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>van Baelen</surname><given-names>B</given-names></name><name><surname>Todd</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term response to galantamine in relation to short-term efficacy data: Pooled analysis in patients with mild to moderate alzheimer's disease</article-title><source>Curr Alzheimer Res</source><year>2011</year><volume>8</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">21222607</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanzi</surname><given-names>RE</given-names></name><name><surname>Bertram</surname><given-names>L</given-names></name></person-group><article-title>New frontiers in alzheimer's disease genetics</article-title><source>Neuron</source><year>2001</year><volume>32</volume><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">11683989</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>MK</given-names></name><name><surname>Tsang</surname><given-names>SW</given-names></name><name><surname>Garcia-Alloza</surname><given-names>M</given-names></name><name><surname>Minger</surname><given-names>SL</given-names></name><name><surname>Nicoll</surname><given-names>JA</given-names></name><name><surname>Esiri</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Selective effects of the apoe epsilon4 allele on presynaptic cholinergic markers in the neocortex of alzheimer's disease</article-title><source>Neurobiol Dis</source><year>2006</year><volume>22</volume><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">16473016</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bishop</surname><given-names>CM</given-names></name></person-group><source>Pattern recognition and machine learning</source><year>2006</year><publisher-name>Springer</publisher-name></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Aronson</surname><given-names>M</given-names></name><name><surname>Fuld</surname><given-names>P</given-names></name><name><surname>Kawas</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>T</given-names></name><name><surname>Morgenstern</surname><given-names>H</given-names></name><etal/></person-group><article-title>Development of dementing illnesses in an 80-year-old volunteer cohort</article-title><source>Ann Neurol</source><year>1989</year><volume>25</volume><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">2712531</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>Y</given-names></name></person-group><article-title>Cognitive reserve and alzheimer disease</article-title><source>Alzheimer Dis Assoc Disord</source><year>2006</year><volume>20</volume><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">16772747</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goekoop</surname><given-names>R</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Rombouts</surname><given-names>SA</given-names></name></person-group><article-title>Cholinergic challenge in alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fmri study</article-title><source>Brain</source><year>2006</year><volume>129</volume><fpage>141</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">16251213</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>J</given-names></name><name><surname>Laurin</surname><given-names>D</given-names></name><name><surname>Verreault</surname><given-names>R</given-names></name><name><surname>Hebert</surname><given-names>R</given-names></name><name><surname>Helliwell</surname><given-names>B</given-names></name><name><surname>Hill</surname><given-names>GB</given-names></name><etal/></person-group><article-title>Risk factors for alzheimer's disease: A prospective analysis from the canadian study of health and aging</article-title><source>Am J Epidemiol</source><year>2002</year><volume>156</volume><fpage>445</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">12196314</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of alzheimer's disease: Report of the nincds-adrda work group under the auspices of department of health and human services task force on alzheimer's disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name></person-group><article-title>"Mini-mental state". A
practical method for grading the cognitive state of patients for the
clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homma</surname><given-names>A</given-names></name><name><surname>Niina</surname><given-names>R</given-names></name><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name></person-group><article-title>Development of a new rating scale for dementia in the elderly: Mental function impairment scale (menfis)</article-title><source>Jpn J Geriatr Psychiatry</source><year>1991</year><volume>2</volume><fpage>1217</fpage><lpage>1222</lpage></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rota</surname><given-names>E</given-names></name><name><surname>Ferrero</surname><given-names>P</given-names></name><name><surname>Ursone</surname><given-names>R</given-names></name><name><surname>Migliaretti</surname><given-names>G</given-names></name></person-group><article-title>Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer's disease: a starting point to explore Bayesian approximation in clinical practice</article-title><source>Bioinformation</source><year>2007</year><volume>2</volume><issue>2</issue><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">18188418</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal-Gidan</surname><given-names>F</given-names></name><name><surname>Cherry</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Hewett</surname><given-names>L</given-names></name><name><surname>Chodosh</surname><given-names>J</given-names></name></person-group><collab>California Workgroup on Guidelines for Alzheimer's Disease
Management</collab><article-title>Alzheimer's disease). management guideline: update
2008</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><issue>3</issue><fpage>e51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">21546322</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. (1)</label><caption><p>Effect size of each factor and its subscales.</p><p>Data are mean&#x000b1;standard deviation of 10 bootstrapped datasets.</p></caption><graphic xlink:href="CAR-11-110_F1"/></fig><fig id="F2" position="float"><label>Fig. (2)</label><caption><p>ROC curves using scores of all 11 subscales as input variables
(full model).</p><p>Data are mean&#x000b1;standard deviation of 1000 bootstrapped datasets.</p></caption><graphic xlink:href="CAR-11-110_F2"/></fig><fig id="F3" position="float"><label>Fig. (3)</label><caption><p>The score of word recognition (difference of the scores of
ADAS-J cog subscales) and its relevance to the incidence of response.</p><p>Data are mean&#x000b1;standard deviation of 20 bootstrapped datasets.</p></caption><graphic xlink:href="CAR-11-110_F3"/></fig><table-wrap id="T1" position="float"><label>Table 1.</label><caption><p>The regression parameters, Wald&#x02018;s chi-square, p values, adjusted odds ratios and their 95% confidence intervals.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">Coefficients</th><th rowspan="1" colspan="1">S.E.</th><th rowspan="1" colspan="1">Chi-square</th><th rowspan="1" colspan="1">p-value</th><th rowspan="1" colspan="1">Adjusted OR</th><th rowspan="1" colspan="1">Lower 95%CI</th><th rowspan="1" colspan="1">Upper 95%CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Recall</td><td align="center" rowspan="1" colspan="1">0.382</td><td align="center" rowspan="1" colspan="1">0.256</td><td align="center" rowspan="1" colspan="1">2.233</td><td align="center" rowspan="1" colspan="1">0.135</td><td align="center" rowspan="1" colspan="1">1.466</td><td align="center" rowspan="1" colspan="1">0.888</td><td align="center" rowspan="1" colspan="1">2.421</td></tr><tr><td align="center" rowspan="1" colspan="1">Language</td><td align="center" rowspan="1" colspan="1">-0.215</td><td align="center" rowspan="1" colspan="1">0.459</td><td align="center" rowspan="1" colspan="1">0.219</td><td align="center" rowspan="1" colspan="1">0.640</td><td align="center" rowspan="1" colspan="1">0.807</td><td align="center" rowspan="1" colspan="1">0.328</td><td align="center" rowspan="1" colspan="1">1.985</td></tr><tr><td align="center" rowspan="1" colspan="1">Comprehension</td><td align="center" rowspan="1" colspan="1">0.392</td><td align="center" rowspan="1" colspan="1">0.475</td><td align="center" rowspan="1" colspan="1">0.682</td><td align="center" rowspan="1" colspan="1">0.409</td><td align="center" rowspan="1" colspan="1">1.480</td><td align="center" rowspan="1" colspan="1">0.584</td><td align="center" rowspan="1" colspan="1">3.755</td></tr><tr><td align="center" rowspan="1" colspan="1">Finding</td><td align="center" rowspan="1" colspan="1">0.544</td><td align="center" rowspan="1" colspan="1">0.415</td><td align="center" rowspan="1" colspan="1">1.722</td><td align="center" rowspan="1" colspan="1">0.189</td><td align="center" rowspan="1" colspan="1">1.724</td><td align="center" rowspan="1" colspan="1">0.764</td><td align="center" rowspan="1" colspan="1">3.887</td></tr><tr><td align="center" rowspan="1" colspan="1">Commands</td><td align="center" rowspan="1" colspan="1">0.218</td><td align="center" rowspan="1" colspan="1">0.281</td><td align="center" rowspan="1" colspan="1">0.602</td><td align="center" rowspan="1" colspan="1">0.438</td><td align="center" rowspan="1" colspan="1">1.244</td><td align="center" rowspan="1" colspan="1">0.717</td><td align="center" rowspan="1" colspan="1">2.157</td></tr><tr><td align="center" rowspan="1" colspan="1">Naming</td><td align="center" rowspan="1" colspan="1">0.270</td><td align="center" rowspan="1" colspan="1">0.495</td><td align="center" rowspan="1" colspan="1">0.298</td><td align="center" rowspan="1" colspan="1">0.585</td><td align="center" rowspan="1" colspan="1">1.310</td><td align="center" rowspan="1" colspan="1">0.497</td><td align="center" rowspan="1" colspan="1">3.457</td></tr><tr><td align="center" rowspan="1" colspan="1">Constructional</td><td align="center" rowspan="1" colspan="1">0.351</td><td align="center" rowspan="1" colspan="1">0.392</td><td align="center" rowspan="1" colspan="1">0.802</td><td align="center" rowspan="1" colspan="1">0.370</td><td align="center" rowspan="1" colspan="1">1.421</td><td align="center" rowspan="1" colspan="1">0.659</td><td align="center" rowspan="1" colspan="1">3.066</td></tr><tr><td align="center" rowspan="1" colspan="1">Ideational</td><td align="center" rowspan="1" colspan="1">0.296</td><td align="center" rowspan="1" colspan="1">0.132</td><td align="center" rowspan="1" colspan="1">5.005</td><td align="center" rowspan="1" colspan="1">0.025<xref ref-type="table-fn" rid="T1F1">*</xref></td><td align="center" rowspan="1" colspan="1">1.344</td><td align="center" rowspan="1" colspan="1">1.037</td><td align="center" rowspan="1" colspan="1">1.742</td></tr><tr><td align="center" rowspan="1" colspan="1">Orientation</td><td align="center" rowspan="1" colspan="1">0.322</td><td align="center" rowspan="1" colspan="1">0.160</td><td align="center" rowspan="1" colspan="1">4.053</td><td align="center" rowspan="1" colspan="1">0.044<xref ref-type="table-fn" rid="T1F1">*</xref></td><td align="center" rowspan="1" colspan="1">1.380</td><td align="center" rowspan="1" colspan="1">1.009</td><td align="center" rowspan="1" colspan="1">1.887</td></tr><tr><td align="center" rowspan="1" colspan="1">Word Recognition</td><td align="center" rowspan="1" colspan="1">0.474</td><td align="center" rowspan="1" colspan="1">0.151</td><td align="center" rowspan="1" colspan="1">9.887</td><td align="center" rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="T1F2">**</xref></td><td align="center" rowspan="1" colspan="1">1.606</td><td align="center" rowspan="1" colspan="1">1.195</td><td align="center" rowspan="1" colspan="1">2.159</td></tr><tr><td align="center" rowspan="1" colspan="1">Task</td><td align="center" rowspan="1" colspan="1">0.560</td><td align="center" rowspan="1" colspan="1">0.456</td><td align="center" rowspan="1" colspan="1">1.507</td><td align="center" rowspan="1" colspan="1">0.220</td><td align="center" rowspan="1" colspan="1">1.751</td><td align="center" rowspan="1" colspan="1">0.716</td><td align="center" rowspan="1" colspan="1">4.282</td></tr></tbody></table><table-wrap-foot><fn id="T1F1"><label>*</label><p>p&#x0003c;0.05</p></fn><fn id="T1F2"><label>**</label><p>p&#x0003c;0.01</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2.</label><caption><p>The regression parameters, Wald&#x02019;s chi-square, p-values, adjusted odds ratios and their 95% confidence intervals in one or
two subscale of ADAS-Jcog</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">Coefficients</th><th rowspan="1" colspan="1">S.E.</th><th rowspan="1" colspan="1">Chi-square</th><th rowspan="1" colspan="1">p-value</th><th rowspan="1" colspan="1">Adjusted OR</th><th rowspan="1" colspan="1">Lower 95%CI</th><th rowspan="1" colspan="1">Upper 95%CI</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Ideational</td><td align="center" rowspan="1" colspan="1">0.269</td><td align="center" rowspan="1" colspan="1">0.118</td><td align="center" rowspan="1" colspan="1">5.224</td><td align="center" rowspan="1" colspan="1">0.022<xref ref-type="table-fn" rid="T2F1">*</xref></td><td align="center" rowspan="1" colspan="1">1.308</td><td align="center" rowspan="1" colspan="1">1.039</td><td align="center" rowspan="1" colspan="1">1.647</td></tr><tr><td align="center" rowspan="1" colspan="1">Orientation</td><td align="center" rowspan="1" colspan="1">0.287</td><td align="center" rowspan="1" colspan="1">0.149</td><td align="center" rowspan="1" colspan="1">3.706</td><td align="center" rowspan="1" colspan="1">0.054</td><td align="center" rowspan="1" colspan="1">1.333</td><td align="center" rowspan="1" colspan="1">0.995</td><td align="center" rowspan="1" colspan="1">1.785</td></tr><tr><td align="center" rowspan="1" colspan="1">Word Recognition</td><td align="center" rowspan="1" colspan="1">0.446</td><td align="center" rowspan="1" colspan="1">0.114</td><td align="center" rowspan="1" colspan="1">15.402</td><td align="center" rowspan="1" colspan="1">0.00009<xref ref-type="table-fn" rid="T2F2">**</xref></td><td align="center" rowspan="1" colspan="1">1.562</td><td align="center" rowspan="1" colspan="1">1.250</td><td align="center" rowspan="1" colspan="1">1.952</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Variables</bold></td><td align="center" rowspan="1" colspan="1"><bold>Coefficients</bold></td><td align="center" rowspan="1" colspan="1"><bold>S.E.</bold></td><td align="center" rowspan="1" colspan="1"><bold>Chi-square</bold></td><td align="center" rowspan="1" colspan="1"><bold>p-value</bold></td><td align="center" rowspan="1" colspan="1"><bold>Adjusted OR</bold></td><td align="center" rowspan="1" colspan="1"><bold>Lower 95%CI</bold></td><td align="center" rowspan="1" colspan="1"><bold>Upper 95%CI</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Ideational</td><td align="center" rowspan="1" colspan="1">0.235</td><td align="center" rowspan="1" colspan="1">0.113</td><td align="center" rowspan="1" colspan="1">4.301</td><td align="center" rowspan="1" colspan="1">0.038<xref ref-type="table-fn" rid="T2F1">*</xref></td><td align="center" rowspan="1" colspan="1">1.265</td><td align="center" rowspan="1" colspan="1">1.013</td><td align="center" rowspan="1" colspan="1">1.581</td></tr><tr><td align="center" rowspan="1" colspan="1">Word Recognition</td><td align="center" rowspan="1" colspan="1">0.412</td><td align="center" rowspan="1" colspan="1">0.108</td><td align="center" rowspan="1" colspan="1">14.525</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="T2F2">**</xref></td><td align="center" rowspan="1" colspan="1">1.510</td><td align="center" rowspan="1" colspan="1">1.221</td><td align="center" rowspan="1" colspan="1">1.866</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Variables</bold></td><td align="center" rowspan="1" colspan="1"><bold>Coefficients</bold></td><td align="center" rowspan="1" colspan="1"><bold>S.E.</bold></td><td align="center" rowspan="1" colspan="1"><bold>Chi-square</bold></td><td align="center" rowspan="1" colspan="1"><bold>p-value</bold></td><td align="center" rowspan="1" colspan="1"><bold>Univariate OR</bold></td><td align="center" rowspan="1" colspan="1"><bold>Lower 95%CI</bold></td><td align="center" rowspan="1" colspan="1"><bold>Upper 95%CI</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Ideational</td><td align="center" rowspan="1" colspan="1">0.232</td><td align="center" rowspan="1" colspan="1">0.106</td><td align="center" rowspan="1" colspan="1">4.765</td><td align="center" rowspan="1" colspan="1">0.029<xref ref-type="table-fn" rid="T2F1">*</xref></td><td align="center" rowspan="1" colspan="1">1.261</td><td align="center" rowspan="1" colspan="1">1.024</td><td align="center" rowspan="1" colspan="1">1.552</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Variables</bold></td><td align="center" rowspan="1" colspan="1"><bold>Coefficients</bold></td><td align="center" rowspan="1" colspan="1"><bold>S.E.</bold></td><td align="center" rowspan="1" colspan="1"><bold>Chi-square</bold></td><td align="center" rowspan="1" colspan="1"><bold>p-value</bold></td><td align="center" rowspan="1" colspan="1"><bold>Univariate OR</bold></td><td align="center" rowspan="1" colspan="1"><bold>Lower 95%CI</bold></td><td align="center" rowspan="1" colspan="1"><bold>Upper 95%CI</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Orientation</td><td align="center" rowspan="1" colspan="1">0.162</td><td align="center" rowspan="1" colspan="1">0.135</td><td align="center" rowspan="1" colspan="1">1.434</td><td align="center" rowspan="1" colspan="1">0.231</td><td align="center" rowspan="1" colspan="1">1.176</td><td align="center" rowspan="1" colspan="1">0.902</td><td align="center" rowspan="1" colspan="1">1.532</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Variables</bold></td><td align="center" rowspan="1" colspan="1"><bold>Coefficients</bold></td><td align="center" rowspan="1" colspan="1"><bold>S.E.</bold></td><td align="center" rowspan="1" colspan="1"><bold>Chi-square</bold></td><td align="center" rowspan="1" colspan="1"><bold>p-value</bold></td><td align="center" rowspan="1" colspan="1"><bold>Univariate OR</bold></td><td align="center" rowspan="1" colspan="1"><bold>Lower 95%CI</bold></td><td align="center" rowspan="1" colspan="1"><bold>Upper 95%CI</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Word Recognition</td><td align="center" rowspan="1" colspan="1">0.406</td><td align="center" rowspan="1" colspan="1">0.106</td><td align="center" rowspan="1" colspan="1">14.683</td><td align="center" rowspan="1" colspan="1">0.0001<xref ref-type="table-fn" rid="T2F2">**</xref></td><td align="center" rowspan="1" colspan="1">1.500</td><td align="center" rowspan="1" colspan="1">1.219</td><td align="center" rowspan="1" colspan="1">1.846</td></tr></tbody></table><table-wrap-foot><fn id="T2F1"><label>*</label><p>p&#x0003c;0.05</p></fn><fn id="T2F2"><label>**</label><p>p&#x0003c;0.01</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3.</label><caption><p>Predictive variables for response to AchEIs in previous studies</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Features</th><th align="left" rowspan="1" colspan="1">
Author/year</th><th align="left" rowspan="1" colspan="1">AChEIs</th><th align="left" rowspan="1" colspan="1">Predictors
for Response to AChEIs</th><th align="left" rowspan="1" colspan="1">Responder
Definition</th><th align="left" rowspan="1" colspan="1">Cut-off</th><th align="left" rowspan="1" colspan="1">Cross Validation</th><th align="left" rowspan="1" colspan="1">Results of
Predictor Performance</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Neuropsychiatric</td><td rowspan="1" colspan="1">Mega/1999</td><td rowspan="1" colspan="1">donepezil</td><td rowspan="1" colspan="1">Behavioral
responses</td><td rowspan="1" colspan="1">NPI at 8 wk</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">
Predictive(decreased delusion, etc.)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Farlow/2001</td><td rowspan="1" colspan="1">rivastigmine</td><td rowspan="1" colspan="1">pretreatment
progression rate</td><td rowspan="1" colspan="1">ADAS-cog at
52 wk</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Predictive
(the rate linked to response)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Wallin/2009</td><td rowspan="1" colspan="1">3 AChEIs</td><td rowspan="1" colspan="1">pretreatment
progression rate</td><td rowspan="1" colspan="1">MMSE at 2, 6
mo</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Predictive
(the rate linked to response)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Sakiyama/2012</td><td rowspan="1" colspan="1">galantamine</td><td rowspan="1" colspan="1">ADAS-J cog
(change from baseline to 4w)</td><td rowspan="1" colspan="1">ADAS-J cog at
24 wk</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">Predictive
(ROC_AUC=0.732)</td></tr><tr><td rowspan="1" colspan="1">Genetic</td><td rowspan="1" colspan="1">Farlow/1999</td><td rowspan="1" colspan="1">metrifonate</td><td rowspan="1" colspan="1">ApoE4
genotype, sex</td><td rowspan="1" colspan="1">ADAS-cog at
12 or 26 wk</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Not
predictive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Oddoze/2000</td><td rowspan="1" colspan="1">donepezil</td><td rowspan="1" colspan="1">ApoE4
genotype</td><td rowspan="1" colspan="1">MMSE at 6 mo</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Predictive
(ApoE4 linked to response)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Wilcock/2000</td><td rowspan="1" colspan="1">galantamine</td><td rowspan="1" colspan="1">ApoE4
genotype</td><td rowspan="1" colspan="1">ADAS-cog at
3,6 mo</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Not
predictive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Aerssens/2001</td><td rowspan="1" colspan="1">galantamine</td><td rowspan="1" colspan="1">ApoE4
genotype (pooled)</td><td rowspan="1" colspan="1">ADAS-cog
after treatment</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Not
predictive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Winblad/2001</td><td rowspan="1" colspan="1">donepezil</td><td rowspan="1" colspan="1">ApoE4
genotype, sex</td><td rowspan="1" colspan="1">
Gottfries-Brane-Steen</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Not
predictive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Farlow/2004</td><td rowspan="1" colspan="1">rivastigmine</td><td rowspan="1" colspan="1">ApoE4
genotype</td><td rowspan="1" colspan="1">ADAS-cog
after treatment</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Not
predictive</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Suh/2006</td><td rowspan="1" colspan="1">galantamine</td><td rowspan="1" colspan="1">ApoE4
genotype</td><td rowspan="1" colspan="1">ADAS-cog,
CIBIC-plus, etc.</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Not
predictive</td></tr><tr><td rowspan="1" colspan="1">Neurochemical</td><td rowspan="1" colspan="1">Sobow/2009</td><td rowspan="1" colspan="1">rivastigmine</td><td rowspan="1" colspan="1">A&#x003b2;42
in plasma</td><td rowspan="1" colspan="1">ADAS-cog at 6
mo</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">
Predictive(higher in responders)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Wallin/2009</td><td rowspan="1" colspan="1">3 AChEIs</td><td rowspan="1" colspan="1">A&#x003b2;42,
T-Tau, P-Tau</td><td rowspan="1" colspan="1">MMSE at 2, 6
mo</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Not
predictive</td></tr><tr><td rowspan="1" colspan="1">Neurological</td><td rowspan="1" colspan="1">
Allhainen/1991</td><td rowspan="1" colspan="1">tacrine</td><td rowspan="1" colspan="1">EEG
alpha-theta ratio</td><td rowspan="1" colspan="1">MMSE after 4
wk</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">
Predictive(higher in responders)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
Allhainen/1993</td><td rowspan="1" colspan="1">tacrine</td><td rowspan="1" colspan="1">EEG
alpha-theta ratio</td><td rowspan="1" colspan="1">MMSE after 7
wk</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">
Predictive(higher in responders)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Knott/2000</td><td rowspan="1" colspan="1">tacrine</td><td rowspan="1" colspan="1">EEG alpha
frequency</td><td rowspan="1" colspan="1">MMSE at 12 wk</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">
Predictive(higher in responders)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Almkvist/2001</td><td rowspan="1" colspan="1">tacrine</td><td rowspan="1" colspan="1">EEG
alpha-theta ratio</td><td rowspan="1" colspan="1">Based on
attention test</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">
Predictive(higher in responders)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Brown/2003</td><td rowspan="1" colspan="1">donepezil</td><td rowspan="1" colspan="1">mAChR binding
in insular cortex</td><td rowspan="1" colspan="1">MMSE&#x00026;ADAS-cog
at 12 wk</td><td rowspan="1" colspan="1">2,4</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Predictive
(lower in responders)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Connelly/2005</td><td rowspan="1" colspan="1">3 AChEIs</td><td rowspan="1" colspan="1">medial
temporal lobe atrophy</td><td rowspan="1" colspan="1">MMSE&#x00026;DDST at
6 mo</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Predictive
(lesser in responders)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Babiloni/2006</td><td rowspan="1" colspan="1">donepezil</td><td rowspan="1" colspan="1">EEG cortical
rhithmicity</td><td rowspan="1" colspan="1">Clinical
Information at 12 mo</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">
Predictive(decreased occipital sources)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Kanetaka/2008</td><td rowspan="1" colspan="1">donepezil</td><td rowspan="1" colspan="1">atrophy and
perfusion at baseline</td><td rowspan="1" colspan="1">MMSE at 14-18
wk</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Predictive (ROC_AUC=0.781)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Shimada/2011</td><td rowspan="1" colspan="1">donepezil</td><td rowspan="1" colspan="1">FDG-PET</td><td rowspan="1" colspan="1">ADAS-cog
baseline</td><td rowspan="1" colspan="1">-1</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Predictive
(frontal occipital FDG uptake)</td></tr><tr><td rowspan="1" colspan="1">Overall</td><td rowspan="1" colspan="1">Wattmo/2011</td><td rowspan="1" colspan="1">3 AChEIs</td><td rowspan="1" colspan="1">males, aged,
ApoE4(-), NSAIDs, etc</td><td rowspan="1" colspan="1">MMSE&#x00026;ADAS-cog
at 36 mo</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Predictive</td></tr></tbody></table></table-wrap></floats-group></article>